You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023290019
Dec 202358010
Jan 20244902
Feb 20245404
Mar 20246006
Apr 20244601
May 20243000
Jun 20246002
Jul 20246006
Aug 20244203
Sep 20246204
Oct 20246806
Nov 20248207
Dec 202456010
Jan 202543012
Feb 2025407
Mar 2025008
Apr 2025005
May 2025003
Jun 2025105
Total10650120